Loading stock data…
Axogen (AXGN)
$39.49-0.24 (-0.60%)
Market ClosedLast close Jul 24
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axogen, Inc. in the Healthcare sector is trading at $39.49 with a market capitalization of $2.3B. Wall Street consensus targets $50.78 (9 analysts), implying a +28.6% move over the next 12 months. The stock is currently 16% below its 52-week high of $46.95, remaining 18.1% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +28.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 25) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $61.46M↑ | $59.90M↓ | $60.08M↑ | $56.66M↑ | $48.56M |
| Gross Profit | $46.19M↑ | $44.41M↓ | $45.99M↑ | $42.02M↑ | $34.93M |
| Operating Income | -$2.83M↑ | -$9.77M↓ | $1.91M↑ | $1.67M↑ | -$1.66M |
| Net Income | -$19.58M↓ | -$13.16M↓ | $708,000↑ | $579,000↑ | -$3.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intende...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.85%
Volume
Today's trading volume
725,253
Recent News
NZS Capital Added Axogen (AXGN) as an Optionality Position
NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […]
Nvidia Returns to NZS Growth Fund
NZS shifts capital toward AI infrastructure and healthcare leaders
Dow Jones AI Giant Nvidia Stock Tumbles To Key Support Level Amid Market Sell-Off
Dow Jones AI giant Nvidia stock tumbled to a key support level during Tuesday's stock market sell-off. A decisive bounce would be bullish.
Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support
Eli Lilly leads three health care stocks to watch as the market appears to be rotating into medicals. Google stock is finding key support too.
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.